Guidelines issued during the pandemic were based on limited evidence.
-
Delaying surgery in stage IA NSCLC better than early SBRT -
Advanced NSCLC: adding radiotherapy to pembrolizumab boosts survival Pooled analysis answers questions remaining after smaller studies.
-
NICE approves nivolumab for advanced pre-treated squamous NSCLC The decision is based on new data from the CheckMate 017 trial and data collected through its use in the Cancer Drugs Fund
-
Insurance barriers leave cancer biomarkers underused Insurance coverage needs improvement.
-
How did the NHS smoking cessation services in Scotland fare? Report published by Public Health Scotland.
-
NSCLC: perioperative allogeneic blood transfusion increases risk for recurrence, death Risk was only increased in patients with early-stage disease.
-
Multidisciplinary team discussions linked to improved OS in stage III NSCLC OS increased by more than a year.
-
Disappointing results from cetuximab plus afatinib for EGFR-positive NSCLC A prior study suggested the combination may thwart TKI resistance.
-
FDA approves chemotherapy-free treatment for malignant pleural mesothelioma First therapy to receive FDA approval in 16 years.
-
Relapsed malignant pleural mesothelioma: pembrolizumab disappoints PROMISE-meso trial yields no survival benefit with pembrolizumab over chemotherapy.
-
Osimertinib boosts DFS in resected EGFR-positive advanced NSCLC Osimertinib efficacy understudied in patients with resected NSCLC.
-
ESMO 2020 — Nivolumab plus chemotherapy and bevacizumab boosts PFS in advanced NSCLC First phase 3 trial of treatment combination.
-
ESMO 2020 — Cemiplimab bests chemotherapy in untreated advanced NSCLC with high PD-L1 Phase 3 results suggest cemiplimab may be another treatment option.
-
ESMO 2020 — Postop conformal RT is not poised to be standard of care in resected NSCLC LungART trial resolves long-standing controversy of PORT vs no PORT in resected NSCLC.